Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022-March 31, 2023

被引：3

作者：

Moro, Pedro L. ^{[1
]}

Carlock, Grace ^{[1
]}

Fifadara, Nimita ^{[1
]}

Habenicht, Tei ^{[1
]}

Zhang, Bicheng ^{[1
]}

Strid, Penelope ^{[2
]}

Marquez, Paige ^{[1
]}

机构：

[1] Natl Ctr Zoonot & Emerging Infect Dis, Div Healthcare Qual Promot, Immunizat Safety Off, Atlanta, GA 30329 USA

[2] Natl Ctr Zoonot & Emerging Infect Dis, Div Healthcare Qual Promot, Preparedness & Response Branch, Atlanta, GA 30329 USA

来源：

VACCINE | 2024年 / 42卷 / 09期

关键词：

Adverse events; Epidemiology; Coronavirus; COVID-19; mRNA COVID-19 vaccines; Bivalent mRNA COVID-19 vaccine; BA.4/BA.5; strains; SARS-CoV-2; Pregnancy; Surveillance; Vaccine safety;

D O I：

10.1016/j.vaccine.2024.02.084

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: Pregnant persons are at increased risk of severe COVID-19 illness. Bivalent mRNA COVID-19 vaccination is recommended for everyone, including pregnant persons. However, data are limited on the safety of bivalent mRNA COVID-19 vaccination during pregnancy. Objective: To evaluate and summarize reports to the Vaccine Adverse Event Reporting System (VAERS), a national spontaneous reporting system, among pregnant persons who received bivalent mRNA COVID-19 vaccine. Methods: VAERS U.S. reports of adverse events (AEs) in pregnant persons who received the bivalent mRNA COVID-19 vaccine from 9/1/2022 - 03/31/2023 were identified. Clinicians reviewed all reports and available medical records. AEs of these reports were compared with AEs reported to VAERS following monovalent mRNA COVID-19 booster vaccination in pregnancy. Results: VAERS received 136 reports for pregnant persons who received bivalent mRNA COVID-19 vaccine; 87 (64 %) after BNT162b2 (Pfizer-BioNTech), and 48 (35 %) after mRNA-1273 (Moderna); 28 (20.6 %) reports were classified as serious. The most common pregnancy -specific outcomes reported included 12 (8.8 %) spontaneous abortions ( <20 weeks gestation), 6 (4.4 %) episodes of preterm delivery, and 5 (3.7 %) reports of preeclampsia. One stillbirth ( >= 20 weeks gestation) was reported. No maternal or infant deaths were reported. There were 6 reports of AEs in infants, which included 3 reports of admissions to the neonatal intensive care unit: two infants with low birth weight, and one infant with a patent ductus arteriosus and patent foramen ovale. Non -pregnancyspecific adverse events were mostly COVID-19 infection and systemic reactions (e.g., headache, fatigue). Pregnancy -specific conditions were reported less frequently after bivalent mRNA COVID-19 vaccination compared to monovalent mRNA COVID-19 booster vaccination (3rd and 4th dose). Conclusions: Based on this review of reports to VAERS, the safety profile of bivalent mRNA COVID-19 vaccination in pregnant persons was comparable to that observed for monovalent mRNA COVID-19 booster vaccination (3rd and 4th dose) in pregnant persons.

引用

页码：2380 / 2384

页数：5

共 50 条

[41] Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015
Haber, Penina
Moro, Pedro L.
Lewis, Paige
Woo, Emily Jane
Jankosky, Christopher
Cano, Maria
VACCINE, 2016, 34 (22) : 2507 - 2512
[42] Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions-VISION Network, September 2022-April 2023
Link-Gelles, Ruth
Weber, Zachary A.
Reese, Sarah E.
Payne, Amanda B.
Gaglani, Manjusha
Adams, Katherine
Kharbanda, Anupam B.
Natarajan, Karthik
DeSilva, Malini B.
Dascomb, Kristin
Irving, Stephanie A.
Klein, Nicola P.
Grannis, Shaun J.
Ong, Toan C.
Embi, Peter J.
Dunne, Margaret M.
Dickerson, Monica
McEvoy, Charlene
Arndorfer, Julie
Naleway, Allison L.
Goddard, Kristin
Dixon, Brian E.
Griggs, Eric P.
Hansen, John
Valvi, Nimish
Najdowski, Morgan
Timbol, Julius
Rogerson, Colin
Fireman, Bruce
Fadel, William F.
Patel, Palak
Ray, Caitlin S.
Wiegand, Ryan
Ball, Sarah
Tenforde, Mark W.
AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (07) : 1062 - 1076
[43] Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions-VISION Network, September 2022-April 2023
Link-Gelles, Ruth
Weber, Zachary A.
Reese, Sarah E.
Payne, Amanda B.
Gaglani, Manjusha
Adams, Katherine
Kharbanda, Anupam B.
Natarajan, Karthik
DeSilva, Malini B.
Dascomb, Kristin
Irving, Stephanie A.
Klein, Nicola P.
Grannis, Shaun J.
Ong, Toan C.
Embi, Peter J.
Dunne, Margaret M.
Dickerson, Monica
McEvoy, Charlene
Arndorfer, Julie
Naleway, Allison L.
Goddard, Kristin
Dixon, Brian E.
Griggs, Eric P.
Hansen, John
Valvi, Nimish
Najdowski, Morgan
Timbol, Julius
Rogerson, Colin
Fireman, Bruce
Fadel, William F.
Patel, Palak
Ray, Caitlin S.
Wiegand, Ryan
Ball, Sarah
Tenforde, Mark W.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2023, 72 (21): : 579 - 588
[44] Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010
Vellozzi, Claudia
Broder, Karen R.
Haber, Penina
Guh, Alice
Nguyen, Michael
Cano, Maria
Lewis, Paige
McNeil, Michael M.
Bryant, Marthe
Singleton, James
Martin, David
DeStefano, Frank
VACCINE, 2010, 28 (45) : 7248 - 7255
[45] Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥ 19 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012 December 31, 2015
Haber, Penina
Arana, Jorge
Pilishvili, Tamara
Lewis, Paige
Moro, Pedro L.
Cano, Maria
VACCINE, 2016, 34 (50) : 6330 - 6334
[46] Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022 (vol 10, ofac698,2023)
Lewis, Nathaniel M.
Murray, Nancy
Adams, Katherine
Surie, Diya
Gaglani, Manjusha
Ginde, Adit A.
McNeal, Tresa
Ghamande, Shekhar
Douin, David J.
Talbot, H. Keipp
Casey, Jonathan D.
Mohr, Nicholas M.
Zepeski, Anne
Shapiro, Nathan, I
Gibbs, Kevin W.
Files, D. Clark
Hager, David N.
Ali, Harith
Prekker, Matthew E.
Frosch, Anne E.
Exline, Matthew C.
Gong, Michelle N.
Mohamed, Amira
Johnson, Nicholas J.
Srinivasan, Vasisht
Steingrub, Jay S.
Peltan, Ithan D.
Brown, Samuel M.
Martin, Emily T.
Monto, Arnold S.
Lauring, Adam S.
Khan, Akram
Hough, Catherine L.
Busse, Laurence W.
Bender, William
Duggal, Abhijit
Wilson, Jennifer G.
Gordon, Alexandra June
Qadir, Nida
Chang, Steven Y.
Mallow, Christopher
Rivas, Carolina
Babcock, Hilary M.
Kwon, Jennie H.
Chappell, James D.
Halasa, Natasha
Grijalva, Carlos G.
Rice, Todd W.
Stubblefield, William B.
Baughman, Adrienne
OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (05):
[47] Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022
Surie, Diya
DeCuir, Jennifer
Zhu, Yuwei
Gaglani, Manjusha
Ginde, Adit A.
Douin, David J.
Talbot, H. Keipp
Casey, Jonathan D.
Mohr, Nicholas M.
Zepeski, Anne
McNeal, Tresa
Ghamande, Shekhar
Gibbs, Kevin W.
Files, D. Clark
Hager, David N.
Ali, Harith
Taghizadeh, Leyla
Gong, Michelle N.
Mohamed, Amira
Johnson, Nicholas J.
Steingrub, Jay S.
Peltan, Ithan D.
Brown, Samuel M.
Martin, Emily T.
Khan, Akram
Bender, William S.
Duggal, Abhijit
Wilson, Jennifer G.
Qadir, Nida
Chang, Steven Y.
Mallow, Christopher
Kwon, Jennie H.
Exline, Matthew C.
Lauring, Adam S.
Shapiro, Nathan I.
Columbus, Cristie
Halasa, Natasha
Chappell, James D.
Grijalva, Carlos G.
Rice, Todd W.
Stubblefield, William B.
Baughman, Adrienne
Womack, Kelsey N.
Rhoads, Jillian P.
Hart, Kimberly W.
Swan, Sydney A.
Lewis, Nathaniel M.
McMorrow, Meredith L.
Self, Wesley H.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (51-52): : 1625 - 1630
[48] Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022
Tenforde, Mark W.
Weber, Zachary A.
Natarajan, Karthik
Klein, Nicola P.
Kharbanda, Anupam B.
Stenehjem, Edward
Embi, Peter J.
Reese, Sarah E.
Naleway, Allison L.
Grannis, Shaun J.
DeSilva, Malini B.
Ong, Toan C.
Gaglani, Manjusha
Han, Jungmi
Dickerson, Monica
Fireman, Bruce
Dascomb, Kristin
Irving, Stephanie A.
Vazquez-Benitez, Gabriela
Rao, Suchitra
Konatham, Deepika
Patel, Palak
Schrader, Kristin E.
Lewis, Ned
Grisel, Nancy
McEvoy, Charlene
Murthy, Kempapura
Griggs, Eric P.
Rowley, Elizabeth A. K.
Zerbo, Ousseny
Arndorfer, Julie
Dunne, Margaret M.
Goddard, Kristin
Ray, Caitlin
Zhuang, Yan
Timbol, Julius
Najdowski, Morgan
Yang, Duck-Hye
Hansen, John
Ball, Sarah W.
Link-Gelles, Ruth
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2022, 71 (51-52): : 1616 - 1624
[49] Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction o COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021
Christie, Athalia
Henley, Jane
Mattocks, Linda
Fernando, Robyn
Lansky, Amy
Ahmad, Farida B.
Adjemian, Jennifer
Anderson, Robert N.
Binder, Alison M.
Carey, Kelly
Dee, Deborah L.
Dias, Taylor
Duck, William M.
Gaughan, Denise M.
Lyons, Brianna Casey
McNaghten, A. D.
Park, Meeyoung M.
Reses, Hannah
Rodgers, Loren
Van Santen, Katharina
Walker, David
Beach, Michael J.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (23): : 858 - 864
[50] Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018
Haber, Penina
Moro, Pedro L.
Ng, Carmen
Dores, Graca M.
Perez-Vilar, Silvia
Marquez, Paige L.
Cano, Maria
VACCINE, 2020, 38 (06) : 1476 - 1480

← 1 2 3 4 5 →